Rapport Therapeutics, Inc. Common Stock

General ticker "RAPP" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.1B (TTM average)

Rapport Therapeutics, Inc. Common Stock follows the US Stock Market performance with the rate: 53.7%.

Estimated limits based on current volatility of 2.7%: low 46.81$, high 49.38$

Factors to consider:

  • Total employees count: 84 (+21.7%) as of 2025
  • Company does not operate outside US (retrieved using AI)
  • Top business risk factors: Product development failure, Regulatory and compliance, Need substantial capital, Market competition, Market acceptance
  • Current price 23.3% above estimated high
  • Earnings for 6 months up through Q2 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [16.38$, 38.42$]
  • 2026-12-31 to 2027-12-31 estimated range: [10.54$, 26.58$]

Similar symbols

Short-term RAPP quotes

Long-term RAPP plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $36.18MM $83.06MM $125.10MM
Operating Income $-36.18MM $-83.06MM $-125.10MM
Non-Operating Income $1.40MM $4.75MM $13.62MM
R&D Expense $28.00MM $60.94MM $94.79MM
Income(Loss) $-34.78MM $-78.31MM $-111.48MM
Taxes $0.01MM $0.00MM $0.00MM
Net Income(Loss)* $-34.79MM $-78.31MM $-111.48MM
Stockholders Equity $-25.63MM $305.43MM $484.65MM
Assets $155.42MM $314.93MM $512.43MM
Operating Cash Flow $-27.18MM $-64.83MM $-87.47MM
Capital expenditure $1.64MM $2.40MM $0.62MM
Investing Cash Flow $-78.86MM $-170.14MM $-187.47MM
Financing Cash Flow $145.14MM $221.62MM $270.79MM
Earnings Per Share** $-1.92 $-3.78 $-2.37

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.